74 related articles for article (PubMed ID: 21605299)
1. Combination antiretroviral therapy as treatment for human immunodeficiency virus-associated mucosa-associated lymphoid tissue type lymphoma of the nasopharynx.
Varma R; Carroll SL; Jacobson IV; Milross CG; Post JJ
Intern Med J; 2011 May; 41(5):437-8. PubMed ID: 21605299
[No Abstract] [Full Text] [Related]
2. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
Rabaud C; Burty C; Grandidier M; Christian B; Penalba C; Béguinot I; Jeanmaire H; May T
Clin Infect Dis; 2005 Jan; 40(2):303-5. PubMed ID: 15655751
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
5. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
6. Mucosa-associated lymphoid tissue lymphoma in patients with human immunodeficiency virus infection.
Boulanger E; Meignin V; Baia M; Molinier-Frenkel V; Leroy K; Oksenhendler E; Gérard L; Copie-Bergman C
Br J Haematol; 2008 Feb; 140(4):470-4. PubMed ID: 18217893
[No Abstract] [Full Text] [Related]
7. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
8. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
King MS; Bernstein BM; Walmsley SL; Sherer R; Feinberg J; Sanne I; Cernohous P; Montaner JS; Brun SC; Sun E
J Infect Dis; 2004 Jul; 190(2):280-4. PubMed ID: 15216462
[TBL] [Abstract][Full Text] [Related]
9. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
11. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.
Hoen B; Dumon B; Harzic M; Venet A; Dubeaux B; Lascoux C; Bourezane Y; Ragnaud JM; Bicart-See A; Raffi F; Beauvais L; Fleury H; Séréni D
J Infect Dis; 1999 Oct; 180(4):1342-6. PubMed ID: 10479169
[TBL] [Abstract][Full Text] [Related]
12. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
[TBL] [Abstract][Full Text] [Related]
14. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
15. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
17. [Raised tattoos in a human-immunodeficiency-virus-infected patient].
García-Lázaro M; Villar C; Natera C; Rivero A
Enferm Infecc Microbiol Clin; 2009 Dec; 27(10):602-4. PubMed ID: 19419796
[No Abstract] [Full Text] [Related]
18. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
19. HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone.
Girard T; Luquet-Besson I; Baran-Marszak F; Raphaël M; Boué F
Eur J Haematol; 2005 Jan; 74(1):70-2. PubMed ID: 15613110
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
